MX2012007671A - Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea. - Google Patents

Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea.

Info

Publication number
MX2012007671A
MX2012007671A MX2012007671A MX2012007671A MX2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A
Authority
MX
Mexico
Prior art keywords
corneal endothelial
endothelial cells
compound
therapeutic agent
agent
Prior art date
Application number
MX2012007671A
Other languages
English (en)
Spanish (es)
Inventor
Yuji Sakamoto
Tetsuo Kida
Hiroaki Takahashi
Takeshi Tarui
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2012007671A publication Critical patent/MX2012007671A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0621Eye cells, e.g. cornea, iris pigmented cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2012007671A 2009-12-29 2010-12-28 Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea. MX2012007671A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009299180 2009-12-29
PCT/JP2010/071424 WO2011080984A1 (en) 2009-12-29 2010-11-24 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
PCT/JP2010/073904 WO2011081221A1 (en) 2009-12-29 2010-12-28 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction

Publications (1)

Publication Number Publication Date
MX2012007671A true MX2012007671A (es) 2012-08-23

Family

ID=43598277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007671A MX2012007671A (es) 2009-12-29 2010-12-28 Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea.

Country Status (10)

Country Link
US (1) US20120288482A1 (https=)
EP (1) EP2519237A1 (https=)
JP (2) JP5750444B2 (https=)
KR (1) KR20120099147A (https=)
CN (1) CN102770136A (https=)
BR (1) BR112012016128A8 (https=)
CA (1) CA2785851A1 (https=)
MX (1) MX2012007671A (https=)
RU (1) RU2563141C2 (https=)
WO (2) WO2011080984A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2788472T (lt) * 2011-12-06 2019-04-10 Astellas Institute For Regenerative Medicine Kryptingos diferenciacijos būdas, skirtas ragenos endotelio ląstelių gamybai
BR112016011096A2 (pt) 2013-11-27 2017-09-19 Kyoto Prefectural Public Univ Corp Aplicação de laminina à cultura de célula endotelial da córnea
WO2015097920A1 (ja) * 2013-12-27 2015-07-02 京都府公立大学法人 角膜内皮細胞の細胞治療併用剤
JP6598381B2 (ja) * 2014-09-24 2019-10-30 興和株式会社 角膜厚調節剤
CN121891508A (zh) * 2014-10-31 2026-04-21 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
EP3213761B1 (en) 2014-10-31 2021-05-19 Kyoto Prefectural Public University Corporation Novel treatment of retina using laminin
PL3416658T3 (pl) * 2016-02-15 2023-09-04 Kyoto Prefectural Public University Corporation Funkcjonalna ludzka komórka śródb‎łonka rogówki i jej zastosowanie

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
CN100411686C (zh) 2001-04-11 2008-08-20 千寿制药株式会社 视觉功能障碍改善剂
JP2004024852A (ja) 2002-04-30 2004-01-29 Amniotec:Kk 角膜内皮様シート、及びその作製方法
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2005118582A1 (ja) * 2004-06-03 2005-12-15 Senju Pharmaceutical Co., Ltd. アミド化合物を含有する角膜知覚回復剤
JPWO2006057270A1 (ja) * 2004-11-26 2008-06-05 旭化成ファーマ株式会社 含窒素3環化合物
JP4766653B2 (ja) * 2005-01-28 2011-09-07 株式会社林原生物化学研究所 眼科用医薬組成物
US20090062295A1 (en) * 2005-03-10 2009-03-05 Mitsubishi Pharma Corporation Pharmaceutical Products
WO2007083685A1 (ja) * 2006-01-19 2007-07-26 Senju Pharmaceutical Co., Ltd. 生体内で細胞増殖可能な角膜内皮製剤
BRPI0714782A2 (pt) * 2006-07-31 2013-07-16 Senju Pharma Co preparaÇço lÍquida aquosa contendo composto de amida
KR20210070407A (ko) 2007-08-29 2021-06-14 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
JP5251632B2 (ja) 2008-05-13 2013-07-31 新日鐵住金株式会社 耐遅れ破壊特性に優れた高強度鋼材、高強度ボルト及びその製造方法
JP2010071424A (ja) 2008-09-19 2010-04-02 Toyota Motor Corp 変速機の制御装置

Also Published As

Publication number Publication date
KR20120099147A (ko) 2012-09-06
JP2013515676A (ja) 2013-05-09
RU2012132443A (ru) 2014-02-10
RU2563141C2 (ru) 2015-09-20
WO2011081221A1 (en) 2011-07-07
JP5750444B2 (ja) 2015-07-22
CA2785851A1 (en) 2011-07-07
BR112012016128A8 (pt) 2017-12-05
JP2015155460A (ja) 2015-08-27
CN102770136A (zh) 2012-11-07
WO2011080984A1 (en) 2011-07-07
BR112012016128A2 (pt) 2016-05-31
EP2519237A1 (en) 2012-11-07
US20120288482A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
MX2012007671A (es) Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea.
EP4512484A3 (en) Excipients for nicotine-containing therapeutic compositions
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
MX2007007458A (es) Derivados de quinazolina para inhibir crecimiento de celulas cancerigenas y metodo para la preparacion de los mismos.
SG151260A1 (en) 5-substituted-2-phenylamino-benzamides as mek inhibitors
MX2011008389A (es) Sal de tipo tosilato de un derivado de 5-pirazolil-2-piridona, util en el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc).
IL219683A0 (en) Ppocess for preparing methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound
WO2009134866A3 (en) Cell membrane engineering
MX2013000001A (es) Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral.
MX2011012264A (es) Derivados spiro[2.4]heptano puenteados como agonistas del receptor de lipoxina a(alx) y/o de formil peptido tipo 2 (fprl2).
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
MX2014005075A (es) Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
WO2012020412A3 (en) Fibrin based scaffold, preparation and use thereof
TW200942529A (en) Pyrrolidinyl derivatives and uses thereof
WO2011025167A3 (ko) 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용 가능한 염을 포함하는 암 예방 또는 치료용 약학 조성물
JP2013515676A5 (https=)
IL209270A (en) Compounds containing tricyclic nitrogen and their use as antibacterial
MX357507B (es) Metodos para tratar hiperucemia en pacientes con gota utilizando halofenato o acido halofenico y un segundo agente de reduccion de urato.
PH12013501509A1 (en) Treatment of cognitive dysfunction in schizophrenia
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
PH12014502282A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SENJU PHARMACEUTICAL CO., LTD.

FG Grant or registration